HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 316 filers reported holding HALOZYME THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 0.23 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $746,690 | +25.6% | 19,547 | +18.8% | 0.00% | 0.0% |
| Q2 2023 | $594,734 | +25.8% | 16,457 | +32.2% | 0.00% | 0.0% |
| Q1 2023 | $472,897 | -74.5% | 12,449 | -61.8% | 0.00% | -75.0% |
| Q4 2022 | $1,854,211 | +56.7% | 32,616 | +9.0% | 0.00% | +33.3% |
| Q3 2022 | $1,183,000 | -33.3% | 29,924 | -25.7% | 0.00% | -25.0% |
| Q2 2022 | $1,774,000 | +216.8% | 40,300 | +185.3% | 0.00% | +300.0% |
| Q1 2022 | $560,000 | -10.5% | 14,125 | -9.4% | 0.00% | 0.0% |
| Q4 2021 | $626,000 | -41.4% | 15,589 | -40.6% | 0.00% | -50.0% |
| Q3 2021 | $1,068,000 | +71.4% | 26,263 | +92.2% | 0.00% | +100.0% |
| Q2 2021 | $623,000 | +12.5% | 13,662 | +3.5% | 0.00% | 0.0% |
| Q1 2021 | $554,000 | -78.4% | 13,202 | -78.0% | 0.00% | -85.7% |
| Q4 2020 | $2,569,000 | +801.4% | 60,125 | +459.1% | 0.01% | +600.0% |
| Q3 2020 | $285,000 | -15.2% | 10,754 | -14.4% | 0.00% | 0.0% |
| Q2 2020 | $336,000 | +127.0% | 12,557 | +53.2% | 0.00% | 0.0% |
| Q1 2020 | $148,000 | – | 8,199 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 19,305,403 | $233,209,000 | 10.86% |
| BB BIOTECH AG | 7,379,832 | $89,148,000 | 3.13% |
| SENZAR ASSET MANAGEMENT, LLC | 550,544 | $6,650,572,000 | 1.72% |
| SNYDER CAPITAL MANAGEMENT L P | 2,232,114 | $26,964,000 | 1.69% |
| Sterling Global Strategies LLC | 22,000 | $266,000 | 0.98% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 9,290,024 | $112,223,000 | 0.98% |
| MSD Partners, L.P. | 965,000 | $11,657,000 | 0.94% |
| DOHENY ASSET MANAGEMENT /CA | 130,950 | $1,582,000 | 0.81% |
| Taylor Wealth Management Partners | 128,110 | $1,548,000 | 0.69% |
| Bellevue Group AG | 318,000 | $3,841,000 | 0.69% |